Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD LSEG Data AD CME Group Education AD Bank of England Statistics AD Investing.com Markets
City & Markets

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Trade Hub UK regulation desk (2026-10-04): Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth… Primary source: original at Nasdaq (nasdaq.com).

By Nasdaq

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

Chief Executive Officer Andrew Obenshain sai

Read at source

Read also
  1. They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace
  2. Why brands like E.l.f., Wendy's and Gap are branching out into original music
  3. Singapore debuts a state-backed dating app for young government workers as it works to slow a demographic crisis
  4. Japan’s Takaichi protests to US after Marine accused of murder in Okinawa
  5. Sports betting is increasingly the norm for Gen Z. Here’s why some financial and mental health experts are worried

Source: Nasdaq